新型冠状病毒肺炎相关急性呼吸窘迫综合征的亚型及对皮质类固醇的不同反应：是时候追求更高精准度了吗？ - Suppr

Suppr

超能文献

COVID-19-related Acute Respiratory Distress Syndrome Subphenotypes and Differential Response to Corticosteroids: Time for More Precision?

作者信息

Reddy Kiran, Hardin Charles Corey, McAuley Daniel Francis

机构信息

Wellcome-Wolfson Institute for Experimental Medicine Queen's University Belfast Belfast, Ireland.

Department of Medicine Massachusetts General Hospital and Harvard Medical School Boston, Massachusetts.

出版信息

Am J Respir Crit Care Med. 2021 Dec 1;204(11):1241-1243. doi: 10.1164/rccm.202109-2213ED.

DOI:10.1164/rccm.202109-2213ED

PMID:34705609

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8786072/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c78e/8786072/09e874fb8c97/rccm.202109-2213EDf1.jpg

相似文献

Am J Respir Crit Care Med. 2021 Dec 1;204(11):1241-1243. doi: 10.1164/rccm.202109-2213ED.

Latent Class Analysis Reveals COVID-19-related Acute Respiratory Distress Syndrome Subgroups with Differential Responses to Corticosteroids.潜类分析揭示 COVID-19 相关急性呼吸窘迫综合征亚组对皮质类固醇的反应存在差异。

Am J Respir Crit Care Med. 2021 Dec 1;204(11):1274-1285. doi: 10.1164/rccm.202105-1302OC.

Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis.基于 COVID-19、其他冠状病毒感染、流感、社区获得性肺炎和急性呼吸窘迫综合征的证据评估 COVID-19 中皮质类固醇的疗效和安全性：系统评价和荟萃分析。

CMAJ. 2020 Jul 6;192(27):E756-E767. doi: 10.1503/cmaj.200645. Epub 2020 May 14.

Pharmacologic Treatments for Acute Respiratory Distress Syndrome.急性呼吸窘迫综合征的药物治疗。

Crit Care Clin. 2021 Oct;37(4):877-893. doi: 10.1016/j.ccc.2021.05.009.

Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia.精准皮质类固醇治疗对重症2019新型冠状病毒肺炎的潜在益处。

Signal Transduct Target Ther. 2020 Feb 21;5(1):18. doi: 10.1038/s41392-020-0127-9.

Corticosteroids in adult respiratory distress syndrome - an inconvenient truth?成人呼吸窘迫综合征中的皮质类固醇——一个令人尴尬的事实？

Int J Pharm Pract. 2021 Dec 4;29(6):642-644. doi: 10.1093/ijpp/riab053.

Corticosteroid use in selected patients with severe acute respiratory distress syndrome related to COVID-19.在部分与新型冠状病毒肺炎相关的严重急性呼吸窘迫综合征患者中使用皮质类固醇。

J Infect. 2020 Aug;81(2):e89-e90. doi: 10.1016/j.jinf.2020.05.023. Epub 2020 May 14.

[Corticosteroids treatment for COVID-19].[用于治疗2019冠状病毒病的皮质类固醇]

Rev Med Chil. 2020 Jul;148(7):893-894. doi: 10.4067/S0034-98872020000700893.

Use of Additional Corticosteroids in Nonresolving COVID-19-Associated Acute Respiratory Distress Syndrome: A Resolved Issue?在未缓解的新型冠状病毒肺炎相关急性呼吸窘迫综合征中使用额外的皮质类固醇：这是一个已解决的问题吗？

Crit Care Med. 2023 Oct 1;51(10):1434-1436. doi: 10.1097/CCM.0000000000005959. Epub 2023 Sep 14.

The Uncertain Role of Corticosteroids in the Treatment of COVID-19.皮质类固醇在治疗新型冠状病毒肺炎中的不确定作用

JAMA Intern Med. 2021 Jan 1;181(1):140. doi: 10.1001/jamainternmed.2020.2444.

引用本文的文献

Advances in acute respiratory distress syndrome: focusing on heterogeneity, pathophysiology, and therapeutic strategies.急性呼吸窘迫综合征的进展：聚焦于异质性、病理生理学和治疗策略。

Signal Transduct Target Ther. 2025 Mar 7;10(1):75. doi: 10.1038/s41392-025-02127-9.

Inflammatory phenotypes may be more important than age and comorbidities in predicting clinical outcomes in hospitalised patients with COVID-19.在预测COVID-19住院患者的临床结局方面，炎症表型可能比年龄和合并症更为重要。

IJID Reg. 2023 Jun 29;8:84-89. doi: 10.1016/j.ijregi.2023.06.003. eCollection 2023 Sep.

NRICM101 ameliorates SARS-CoV-2-S1-induced pulmonary injury in K18-hACE2 mice model.NRICM101改善了K18-hACE2小鼠模型中SARS-CoV-2-S1诱导的肺损伤。

Front Pharmacol. 2023 Jun 21;14:1125414. doi: 10.3389/fphar.2023.1125414. eCollection 2023.

Different treatment response to systemic corticosteroids according to white blood cell counts in severe COVID-19 patients.严重 COVID-19 患者根据白细胞计数对全身皮质类固醇的不同治疗反应。

Ann Med. 2022 Dec;54(1):2998-3006. doi: 10.1080/07853890.2022.2137736.

A Randomized Trial of Mesenchymal Stromal Cells for Moderate to Severe Acute Respiratory Distress Syndrome from COVID-19.一项间充质干细胞治疗 COVID-19 所致中重度急性呼吸窘迫综合征的随机临床试验。

Am J Respir Crit Care Med. 2023 Feb 1;207(3):261-270. doi: 10.1164/rccm.202201-0157OC.

本文引用的文献

Am J Respir Crit Care Med. 2021 Dec 1;204(11):1274-1285. doi: 10.1164/rccm.202105-1302OC.

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.托珠单抗治疗 COVID-19 住院患者的疗效（RECOVERY）：一项随机、对照、开放标签、平台试验。

Lancet. 2021 May 1;397(10285):1637-1645. doi: 10.1016/S0140-6736(21)00676-0.

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.COVID-19 重症患者的白细胞介素 6 受体拮抗剂。

N Engl J Med. 2021 Apr 22;384(16):1491-1502. doi: 10.1056/NEJMoa2100433. Epub 2021 Feb 25.

Characteristics, Outcomes, and Trends of Patients With COVID-19-Related Critical Illness at a Learning Health System in the United States.美国学习型医疗系统中 COVID-19 相关危重症患者的特征、结局和趋势。

Ann Intern Med. 2021 May;174(5):613-621. doi: 10.7326/M20-5327. Epub 2021 Jan 19.

Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.羟考酮治疗对严重 COVID-19 患者死亡率和器官支持的影响：REMAP-CAP COVID-19 皮质类固醇随机临床试验。

JAMA. 2020 Oct 6;324(13):1317-1329. doi: 10.1001/jama.2020.17022.

Prevalence of phenotypes of acute respiratory distress syndrome in critically ill patients with COVID-19: a prospective observational study.新冠肺炎危重症患者急性呼吸窘迫综合征表型的患病率：一项前瞻性观察研究。

Lancet Respir Med. 2020 Dec;8(12):1209-1218. doi: 10.1016/S2213-2600(20)30366-0. Epub 2020 Aug 27.

Dexamethasone in Hospitalized Patients with Covid-19.地塞米松在 COVID-19 住院患者中的应用。

N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.

Machine Learning Classifier Models Can Identify Acute Respiratory Distress Syndrome Phenotypes Using Readily Available Clinical Data.机器学习分类器模型可以使用现成的临床数据识别急性呼吸窘迫综合征表型。

Am J Respir Crit Care Med. 2020 Oct 1;202(7):996-1004. doi: 10.1164/rccm.202002-0347OC.

Development and validation of parsimonious algorithms to classify acute respiratory distress syndrome phenotypes: a secondary analysis of randomised controlled trials.简约算法开发与验证用于急性呼吸窘迫综合征表型分类：随机对照试验的二次分析。

Lancet Respir Med. 2020 Mar;8(3):247-257. doi: 10.1016/S2213-2600(19)30369-8. Epub 2020 Jan 13.

Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial.急性呼吸窘迫综合征亚表型与辛伐他汀反应的差异：一项随机对照试验的二次分析。

Lancet Respir Med. 2018 Sep;6(9):691-698. doi: 10.1016/S2213-2600(18)30177-2. Epub 2018 Aug 2.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验